Evidence map›Paper›PMID 41483069›Full record

ReviewReviews in endocrine & metabolic disorders2026

Too much vitamin D? a drug safety review.

Luisella Cianferotti, John P Bilezikian, Giuseppe Bifolco, Eleonora Fini, Cristiana Cipriani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luisella CianferottiBone Metabolic Diseases Unit, Department of Experimental and Clinical Biomedical Sciences, University Hospital of Florence, University of Florence, Viale GB Morgagni 50, Florence, 50134, Italy. luisella.cianferotti@unifi.it.ORCID 0000-0001-7424-6212
John P BilezikianDivision of Endocrinology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.ORCID 0000-0002-1570-2617
Giuseppe BifolcoBone Metabolic Diseases Unit, Department of Experimental and Clinical Biomedical Sciences, University Hospital of Florence, University of Florence, Viale GB Morgagni 50, Florence, 50134, Italy.ORCID 0000-0002-7430-0538
Eleonora FiniBone Metabolic Diseases Unit, Department of Experimental and Clinical Biomedical Sciences, University Hospital of Florence, University of Florence, Viale GB Morgagni 50, Florence, 50134, Italy.ORCID 0009-0009-6345-6877
Cristiana CiprianiDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. cristiana.cipriani@uniroma1.it.ORCID 0000-0002-0141-1202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D is an essential pro-hormone that helps to regulate mineral metabolism and skeletal health. Epidemiological data suggest that many individuals have insufficient serum levels of 25-hydroxy vitamin D, the marker of vitamin D status, for most of the year. Recognition of this observation has led to replacement regimens for vitamin D that have often led to its overuse even in disorders not related to bone homeostasis. Since vitamin D toxicity is rare, safety issues related to vitamin D supplementation have not been carefully addressed recently. Overall safety issues related to administration of vitamin D pro-hormones from nutritional sources and from supplements are reviewed, along with recommendations for correct intakes. Traditional and new areas in which an improper use of vitamin D may occur are specifically addressed. Supplementation with vitamin D pro-hormones is effective and safe at usual daily, weekly or monthly doses that are recommended to maintain optimal mineral homeostasis. Monitoring is generally not mandatory once the desired level of serum 25(OH)D is obtained. However, clinical circumstances often change from year to year, in which cases confirmation of the adequacy of 25(OH)D is reasonable. When calcidiol is used, long term, monitoring is expected. Ingestion of excessive amounts of vitamin D, either through overprescribing or overdosing, is potentially harmful.

Indexed as

Vitamin DVitamin D DeficiencyDietary SupplementsHumansVitamin D25-hydroxy-vitamin DBoneSafetyToxicityVitamin D

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.